Uses of Sucrasol: - Intestinal ulcers - Stomach ulcers Peptic ulcer, Chronic gastritis, GI haemorrhage from stress ulceration Hypersensitivity.

Chelating complex

Sucralfate protects GI lining against peptic acid, pepsin and bile salts by binding with positively-charged proteins in exudates forming a viscous paste-like adhesive substance thus forming a protective coating.

How to use Sucralfate: Take this medicine in the dose and duration as advised by your doctor. Check the label for directions before use. Measure it with a measuring cup and take it by mouth. Shake well before use. Sucralfate is to be taken empty stomach. Administration: Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals. Adult Dose: Oral Chronic gastritis; Peptic ulcer Adult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose of 1 g bid may be given to prevent the recurrence of duodenal ulcers. Max: 8 g daily. Prophylaxis of gastrointestinal haemorrhage from stress ulceration Adult: 1 g 6 times daily. Not to exceed 8 g daily. Child Dose: Oral Chronic gastritis; Peptic ulcer Child: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily. Prophylaxis of gastrointestinal haemorrhage from stress ulceration Child: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily. Renal Dose: Renal failure: Use with caution; aluminum salt may accumulate

Avoid antacids within 30 min of sucralfate admin. May reduce absorption of tetracyclines, ranitidine, ketoconazole, theophylline, phenytoin, cimetidine and digoxin (ensure a dosing interval of at least 2 hr between admin of sucralfate and other non-antacid medications).

Hypersensitivity.

Common - Constipation 1-10% Constipation (2%) <1% Diarrhea,Dizziness,Dry mouth,Flatulence,Headache,Indigestion,Insomnia,Nausea,Vertigo,Vomiting Frequency Not Defined Bezoars formation,Gastrointestinal discomfort

Although animal studies show no evidence of foetal malformation, safety in pregnant women has not been established and Sucralfate should be used in pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised when sucralfate is administered to nursing mothers.

Precaution: Systemic aluminum toxicity may occur in patients with chronic renal failure. Neonates, children; pregnancy and lactation. Lactation: Probably safe because drug is minimally absorbed; unknown whether drug is excreted in breast milk

In a clinical trial on healthy men of overdose with Sucralfate, most cases remained asymptomatic but symptoms of abdominal pain, nausea, and vomiting were reported in a few cases. Acute oral toxicity studies in animals using doses up to 12 gm/kg body weight could not find a lethal dose. Risks associated with overdose should therefore be minimal.

Store in a cool and dry place, protected from light.

Chelating complex

Sucralfate protects GI lining against peptic acid, pepsin and bile salts by binding with positively-charged proteins in exudates forming a viscous paste-like adhesive substance thus forming a protective coating.

Safety in pregnant women has not been established and Sucralfate should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised when Sucralfate is administered to breast-feeding women.